CytomX Therapeutics, Inc.— Sankey Diagram
Annual mode · period ending 2025-12-31 · SEC EDGAR
FY2025 - Q4(Oct 25 · Nov 25 · Dec 25)
Total Assets
$152M
↑+25.7% +$31Mvs FY2024
Total Liabilities
$53M
↓-56.6% -$68Mvs FY2024
Equity
$99M
↑+21812.3% +$99Mvs FY2024
Cash
$13M
↓-66.7% -$25Mvs FY2024
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2025 | FY2024 |
|---|---|---|
| Total Assets | $152M | $121M |
| Current Assets | $144M | $107M |
| Cash | $13M | $38M |
| ST Investments | $0 | $0 |
| Receivables | $2M | $3M |
| Inventory | $0 | $0 |
| Other Current | $129M | $66M |
| Non-Current Assets | $8M | $13M |
| PPE | $1M | $2M |
| Goodwill | $949K | $949K |
| Intangibles | $0 | $0 |
| Investments | $0 | $0 |
| Other Non-Current | $5M | $10M |
| Total Liab+Eq | $152M | $121M |
| Current Liab. | $47M | $86M |
| Accounts Payable | $1M | $1M |
| Short-Term Debt | $0 | $0 |
| Deferred Revenue | $27M | $67M |
| Other CL | $18M | $17M |
| Non-Current Liab. | $6M | $35M |
| Long-Term Debt | $0 | $0 |
| Other LT Liab. | $6M | $35M |
| Equity | $99M | $-456K |
| Retained Earnings | $712M | $692M |
| Other Equity | $0 | $0 |
QuarterCharts · SEC EDGAR data · CTMX · Comparing FY2025 vs FY2024